SuperworthEvolus profit margin EOLS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.
- Net margin, 12 months
- −10.8%
- Operating margin, 12 months
- −5.9%
- Net margin on a year earlier
- +11.5 pts
- Peer median
- 11.6%
Over the twelve months to Jun 30, 2026, Evolus kept −10.8% of its revenue as net profit, with an operating margin of −5.9% and a gross margin of 66.7%.
The median for 10 large drugmakers of a similar size is 11.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −17.4% | −11.0% | 66.3% |
| FY2024 | −18.9% | −12.9% | 68.5% |
| FY2023 | −30.5% | −24.4% | 69.5% |
| FY2022 | −50.1% | −44.0% | 62.4% |
| FY2021 | −47.0% | −44.6% | 56.3% |
| FY2020 | n/a | n/a | 67.6% |
| FY2019 | n/a | n/a | 77.1% |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −10.8% | +11.5 pts | −5.9% | |
| Q1 FY26 | −14.4% | +6.0 pts | −8.1% | |
| Q4 FY25 | −17.4% | +1.6 pts | −11.0% | |
| Q3 FY25 | −20.5% | +1.8 pts | −13.7% | |
| Q2 FY25 | −22.3% | +0.1 pts | −15.5% | |
| Q1 FY25 | −20.4% | +6.9 pts | −14.8% | |
| Q4 FY24 | −18.9% | +11.6 pts | −12.9% | |
| Q3 FY24 | −22.3% | +11.8 pts | −16.4% | |
| Q2 FY24 | −22.4% | +16.9 pts | −16.3% | |
| Q1 FY24 | −27.3% | +18.5 pts | −21.0% | |
| Q4 FY23 | −30.5% | +19.5 pts | −24.4% | |
| Q3 FY23 | −34.1% | +22.8 pts | −27.7% |
Against its peers
Companies in Drug Manufacturers - General nearest Evolus' size, closest first, today.
| Company | Profit margin |
|---|---|
| EOLSEvolus | −10.8% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| NATRNatures Sunshine Products | 3.7% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| Peer median | 11.6% |
Where Evolus ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Evolus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.